Johnson & Johnson (JNJ) Goodwill & Intangibles (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Goodwill & Intangibles came in at $97.6 billion in Q1 2026, up 20.19% year-on-year from $81.2 billion in Q1 2025, and down 1.57% quarter-over-quarter from $99.2 billion in Q4 2025.

Johnson & Johnson (JNJ) Goodwill & Intangibles (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Goodwill & Intangibles across 18 years of filings, most recently posting $97.6 billion for Q1 2026.

  • Goodwill & Intangibles for Q1 2026 came in at $97.6 billion, up 20.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.6 billion (up 20.19% YoY), and the FY2025 annual result was $99.2 billion, up 21.21% from the prior year.
  • Goodwill & Intangibles came in at $97.6 billion for Q1 2026 at Johnson & Johnson, down from $99.2 billion in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $99.2 billion in Q4 2025 to a low of $70.7 billion in Q4 2023.
  • The 5-year median for Goodwill & Intangibles is $81.5 billion (2024), against an average of $83.1 billion.
  • Across the five-year window, Goodwill & Intangibles soared 54.66% in 2022 and declined 23.78% in 2024, its largest moves.
  • Johnson & Johnson's Goodwill & Intangibles stood at $73.7 billion in 2022, then retreated by 4.05% to $70.7 billion in 2023, then advanced by 15.67% to $81.8 billion in 2024, then climbed by 21.21% to $99.2 billion in 2025, then slipped by 1.57% to $97.6 billion in 2026.
  • The last three Goodwill & Intangibles figures came in at $97.6 billion (Q1 2026), $99.2 billion (Q4 2025), and $96.8 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 97.62 Bn
Dec 28, 2025 99.18 Bn
Sep 28, 2025 96.79 Bn
Jun 29, 2025 97.95 Bn
Mar 30, 2025 81.22 Bn
Dec 29, 2024 81.82 Bn
Sep 29, 2024 84.29 Bn
Jun 30, 2024 83.98 Bn
Mar 31, 2024 70.90 Bn
Dec 31, 2023 70.73 Bn
Oct 1, 2023 71.15 Bn
Jul 2, 2023 91.69 Bn
Apr 2, 2023 93.02 Bn
Jan 1, 2023 74.54 Bn
Oct 2, 2022 73.72 Bn
Jul 3, 2022 76.57 Bn
Apr 3, 2022 79.36 Bn
Jan 2, 2022 71.83 Bn
Oct 3, 2021 83.35 Bn
Jul 4, 2021 86.06 Bn